U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07211139) titled 'Head and Neck Advanced Research for Multi-Omics and Optimized Immunotherapy' on Sept. 17.
Brief Summary: Head and neck squamous cell carcinoma is a heterogeneous cancer with varying prognoses depending on anatomical location and characteristics, and advanced cancers have a poor prognosis. This study aimed to examine changes in the tumor microenvironment and systemic immune system before and after combination therapy with immune checkpoint inhibitors, the standard first-line treatment for head and neck cancer. The rationale for this research and development project is as follows:
1. While immune checkpoint inhibitors have improved su...